Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Rev. chil. infectol ; 40(5): 491-497, oct. 2023. tab
Artigo em Espanhol | LILACS | ID: biblio-1521876

RESUMO

INTRODUCCIÓN: La resistencia a fármacos antituberculosos está influenciada por las características personales y las condiciones de salud de países en vías de desarrollo. OBJETIVO: Determinar los factores asociados a TB-pre extensamente resistente (TB-PRE XDR) en pacientes del Hospital Nacional Dos de Mayo (HNDM) entre 2017 y 2019. PACIENTES Y MÉTODO: Se desarrolló un estudio caso control no pareado, definiendo como caso al paciente con TB- PRE XDR y como control al paciente con TB-S. Se recolectaron variables epidemiológicas, clínicas y radiológicas. RESULTADOS: Se analizaron 51 casos y 102 controles. El análisis bivariado determinó como factores con p 51 años (OR: 0,17, IC95%: 0,05-0,51), uso de drogas (OR:2,5, IC95%: 1,1-5,4), antecedente de TB (OR: 20, IC95%: 8,4-47), reclusión previa (OR: 8, IC95%: 2,7-23,8), infección por VIH (OR: 0,2, IC95%: 0,08-1) y uso previo de fármacos antituberculosos (OR: 21, IC95%: 8,8-50). El análisis de regresión logística identificó como factores asociados a TB-PRE XDR al contacto de TB, antecedente de TB, tiempo de enfermedad y uso previo de fármacos antituberculosos. CONCLUSIÓN: Las medidas para limitar el desarrollo de TB-PRE XDR en pacientes con TB-S deben incidir sobre el antecedente de TB, contacto con TB, tiempo de enfermedad y uso previo de anti-TB no controlados; sin embargo, existen resultados no concluyentes sobre el hábito nocivo y la comorbilidad, siendo necesario más estudios para determinar su influencia como factores asociados identificables.


BACKGROUND: Resistance to anti-TB drugs is influenced by personal characteristics and health conditions in developing countries. AIM: To determine the factors associated with pre-extensively drug-resistant tuberculosis (PRE XDR-TB) at Hospital Nacional Dos de Mayo (HNDM) in patients between the 2017 and 2019. METHODS: An unpaired case control study was developed; defining as case PRE XDR-TB patient and as control S-TB patient. Epidemiological, clinical and radiological variables were collected. RESULTS: We analyzed 51 cases and 102 controls. The bivariate analysis showed as factors with p 51 years (OR: 0.17, 95% CI: 0.05-0.51), drug use (OR: 2.5, 95% CI: 1.1-5.4), previous history of TB (OR: 20, 95% CI: 8.4-47), previous confinement (OR: 8, 95% CI: 2.7-23.8), HIV infection (OR: 0.2, 95% CI: 0.08-1) and previous use of antiTB drugs (OR: 21, 95% CI: 8.8-50). The logistic regression analysis identified as associated factors with PRE XDR-TB the previous contact with TB, a history of TB, length of illness and previous use of tuberculosis antibiotics. CONCLUSION: The measures to limit the development of TB-PRE XDR in patients with TB-S must include the previous history of TB, TB contact, length of illness and previous use of uncontrolled antibiotics against TB; however, there are inconclusive results about the harmful habits and comorbidity, requiring more studies to determine their influence as identifiable associated factors.


Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Tuberculose Extensivamente Resistente a Medicamentos/epidemiologia , Peru/epidemiologia , Estudos de Casos e Controles , Fatores Epidemiológicos , Análise Multivariada , Análise de Regressão , Fatores de Risco , Tuberculose Extensivamente Resistente a Medicamentos/diagnóstico por imagem , Hospitais Públicos
2.
Pediatr Infect Dis J ; 39(6): 512-513, 2020 06.
Artigo em Inglês | MEDLINE | ID: mdl-32032176

RESUMO

Bedaquiline and delamanid used to treat extensively drug-resistant tuberculosis are known to cause prolonged QTc. Two children with extensively drug-resistant tuberculosis were put on bedaquiline and delamanid and had prolonged QTc on the Bazett formula but normal QTc by the Fridericia formula. Both had no adverse effects. Correct formula for monitoring QTc should be used thereby preventing unnecessary withholding of medicines.


Assuntos
Antituberculosos/administração & dosagem , Diarilquinolinas/administração & dosagem , Tuberculose Extensivamente Resistente a Medicamentos/tratamento farmacológico , Nitroimidazóis/administração & dosagem , Oxazóis/administração & dosagem , Adolescente , Antituberculosos/uso terapêutico , Criança , Diarilquinolinas/uso terapêutico , Tuberculose Extensivamente Resistente a Medicamentos/diagnóstico por imagem , Feminino , Humanos , Masculino , Nitroimidazóis/uso terapêutico , Oxazóis/uso terapêutico , Escarro/microbiologia , Tomografia Computadorizada por Raios X
3.
PLoS One ; 15(1): e0224445, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-31978149

RESUMO

Availability of trained radiologists for fast processing of CXRs in regions burdened with tuberculosis always has been a challenge, affecting both timely diagnosis and patient monitoring. The paucity of annotated images of lungs of TB patients hampers attempts to apply data-oriented algorithms for research and clinical practices. The TB Portals Program database (TBPP, https://TBPortals.niaid.nih.gov) is a global collaboration curating a large collection of the most dangerous, hard-to-cure drug-resistant tuberculosis (DR-TB) patient cases. TBPP, with 1,179 (83%) DR-TB patient cases, is a unique collection that is well positioned as a testing ground for deep learning classifiers. As of January 2019, the TBPP database contains 1,538 CXRs, of which 346 (22.5%) are annotated by a radiologist and 104 (6.7%) by a pulmonologist-leaving 1,088 (70.7%) CXRs without annotations. The Qure.ai qXR artificial intelligence automated CXR interpretation tool, was blind-tested on the 346 radiologist-annotated CXRs from the TBPP database. Qure.ai qXR CXR predictions for cavity, nodule, pleural effusion, hilar lymphadenopathy was successfully matching human expert annotations. In addition, we tested the 12 Qure.ai classifiers to find whether they correlate with treatment success (information provided by treating physicians). Ten descriptors were found as significant: abnormal CXR (p = 0.0005), pleural effusion (p = 0.048), nodule (p = 0.0004), hilar lymphadenopathy (p = 0.0038), cavity (p = 0.0002), opacity (p = 0.0006), atelectasis (p = 0.0074), consolidation (p = 0.0004), indicator of TB disease (p = < .0001), and fibrosis (p = < .0001). We conclude that applying fully automated Qure.ai CXR analysis tool is useful for fast, accurate, uniform, large-scale CXR annotation assistance, as it performed well even for DR-TB cases that were not used for initial training. Testing artificial intelligence algorithms (encapsulating both machine learning and deep learning classifiers) on diverse data collections, such as TBPP, is critically important toward progressing to clinically adopted automatic assistants for medical data analysis.


Assuntos
Tuberculose Extensivamente Resistente a Medicamentos/diagnóstico por imagem , Pulmão/diagnóstico por imagem , Derrame Pleural/diagnóstico por imagem , Tuberculose/diagnóstico por imagem , Algoritmos , Inteligência Artificial , Gerenciamento de Dados , Bases de Dados Factuais , Aprendizado Profundo , Tuberculose Extensivamente Resistente a Medicamentos/diagnóstico , Tuberculose Extensivamente Resistente a Medicamentos/fisiopatologia , Feminino , Humanos , Pulmão/fisiopatologia , Masculino , Derrame Pleural/diagnóstico , Derrame Pleural/fisiopatologia , Radiografia Torácica/métodos , Radiologistas , Tuberculose/diagnóstico , Tuberculose/fisiopatologia
5.
Lancet Infect Dis ; 15(12): 1485-91, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26607130

RESUMO

Extensively drug-resistant (XDR) tuberculosis is becoming increasingly prevalent worldwide, but little is known about XDR tuberculosis in young children. In this Grand Round we describe a 2-year-old child from the USA who developed pneumonia after a 3 month visit to India. Symptoms resolved with empirical first-line tuberculosis treatment; however, a XDR strain of Mycobacterium tuberculosis grew in culture. In the absence of clinical or microbiological markers, low-radiation exposure pulmonary CT imaging was used to monitor treatment response, and guide an individualised drug regimen. Management was complicated by delays in diagnosis, uncertainties about drug selection, and a scarcity of child-friendly formulations. Treatment has been successful so far, and the child is in remission. This report of XDR tuberculosis in a young child in the USA highlights the risks of acquiring drug-resistant tuberculosis overseas, and the unique challenges in management of tuberculosis in this susceptible population.


Assuntos
Tuberculose Extensivamente Resistente a Medicamentos/diagnóstico , Pneumonia Bacteriana/diagnóstico , Tuberculose Pulmonar/diagnóstico , Antituberculosos/uso terapêutico , Pré-Escolar , Tuberculose Extensivamente Resistente a Medicamentos/diagnóstico por imagem , Tuberculose Extensivamente Resistente a Medicamentos/tratamento farmacológico , Tuberculose Extensivamente Resistente a Medicamentos/microbiologia , Feminino , Humanos , Índia , Mycobacterium tuberculosis/patogenicidade , Mycobacterium tuberculosis/fisiologia , Pneumonia Bacteriana/diagnóstico por imagem , Pneumonia Bacteriana/tratamento farmacológico , Pneumonia Bacteriana/microbiologia , Radiografia , Viagem , Tuberculose Pulmonar/diagnóstico por imagem , Tuberculose Pulmonar/tratamento farmacológico , Tuberculose Pulmonar/microbiologia , Estados Unidos
6.
Ugeskr Laeger ; 177(17)2015 Apr 20.
Artigo em Dinamarquês | MEDLINE | ID: mdl-25922164

RESUMO

In 2013 the first case of extensively drug-resistant tuberculosis was observed in Denmark. A 40-year-old male immigrant had previously been treated with several different antibiotics in his native country Russia. Because of earlier imprisonment in Russia and the fear of reincarceration he did not fully inform the Danish authorities about his disease and treatment. Therefore, he was initially treated with first-line drugs. Once the whole truth emerged and the result of the resistance test was available he was admitted to a highly specialized unit for further treatment.


Assuntos
Tuberculose Extensivamente Resistente a Medicamentos/diagnóstico , Tuberculose Pulmonar/diagnóstico , Adulto , Antituberculosos/uso terapêutico , Dinamarca , Tuberculose Extensivamente Resistente a Medicamentos/diagnóstico por imagem , Tuberculose Extensivamente Resistente a Medicamentos/tratamento farmacológico , Humanos , Masculino , Radiografia , Federação Russa/etnologia , Tuberculose Pulmonar/diagnóstico por imagem , Tuberculose Pulmonar/tratamento farmacológico
7.
Sci Transl Med ; 6(265): 265ra167, 2014 Dec 03.
Artigo em Inglês | MEDLINE | ID: mdl-25473035

RESUMO

Oxazolidinone antibiotics such as linezolid have shown significant therapeutic effects in patients with extensively drug-resistant (XDR) tuberculosis (TB) despite modest effects in rodents and no demonstrable early bactericidal activity in human phase 2 trials. We show that monotherapy with either linezolid or AZD5847, a second-generation oxazolidinone, reduced bacterial load at necropsy in Mycobacterium tuberculosis-infected cynomolgus macaques with active TB. This effect coincided with a decline in 2-deoxy-2-[(18)F]-fluoro-d-glucose positron emission tomography (FDG PET) imaging avidity in the lungs of these animals and with reductions in pulmonary pathology measured by serial computed tomography (CT) scans over 2 months of monotherapy. In a parallel phase 2 clinical study of linezolid in patients infected with XDR-TB, we also collected PET/CT imaging data from subjects receiving linezolid that had been added to their failing treatment regimens. Quantitative comparisons of PET/CT imaging changes in these human subjects were similar in magnitude to those observed in macaques, demonstrating that the therapeutic effect of these oxazolidinones can be reproduced in this model of experimental chemotherapy. PET/CT imaging may be useful as an early quantitative measure of drug efficacy against TB in human patients.


Assuntos
Tuberculose Extensivamente Resistente a Medicamentos/tratamento farmacológico , Oxazolidinonas/uso terapêutico , Tomografia por Emissão de Pósitrons , Tomografia Computadorizada por Raios X , Acetamidas/administração & dosagem , Algoritmos , Animais , Antibacterianos/uso terapêutico , Tuberculose Extensivamente Resistente a Medicamentos/diagnóstico por imagem , Fluordesoxiglucose F18 , Humanos , Linezolida , Linfonodos/patologia , Macaca , Imagem Multimodal , Oxazolidinonas/administração & dosagem , Células-Tronco , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...